MedPath

Migraine Drug Ubrelvy May Stop Headaches Before They Start

Ubrelvy (ubrogepant) showed 73% more effectiveness in reducing migraine disability within 2 hours compared to placebo in a clinical trial, potentially improving quality of life for migraine sufferers.


Reference News

Breakthrough study reveals drug that could halt migraines before they start

A study reveals *ubrogepant* (brand name *Uberlevi*) may prevent migraines if taken at pre-migraine symptoms, with 65% reporting minimal pain 24 hours later. The drug targets CGRP protein, offering potential for proactive migraine management.

Migraine Drug Ubrelvy May Stop Headaches Before They Start

Ubrelvy (ubrogepant) showed 73% more effectiveness in reducing migraine disability within 2 hours compared to placebo in a clinical trial, potentially improving quality of life for migraine sufferers.

© Copyright 2025. All Rights Reserved by MedPath